key: cord-0714270-fzd2hzcc
authors: Ghafari, Mahan; Kadivar, Alireza; Katzourakis, Aris
title: Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
date: 2021-02-15
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00053-0
sha: f2b49520ab4b0f41d1b38a7a0757c93d72938a8e
doc_id: 714270
cord_uid: fzd2hzcc

nan

: A regression analysis based on the percentage of city-level seroprevalence estimates in late April/early June and percentage of provincial-level estimates by the end of spring (20 June 2020) according to seasonal excess mortality data. The line of best fit (dashed line) corresponds to 2 = 0.67. This analysis excludes Fars and Sistan-Baluchsitan provinces which did not show significant levels of excess mortality in spring [3] . If we include those two provinces with an assumed zero excess deaths in spring (and include the two cities, Shiraz and Zahedan, with their corresponding seroprevalence estimates), then the correlation drops to 2 = 0.63. Also, if we remove the 72.6% exposure in Rasht based on seroprevalence as an outlier data, the correlation increases to 2 = 0.71 (and 2 = 0.66 if we assume the two provinces have zero excess deaths). In all these instances, the p-value is very significant ( < .001).

SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population based cross-sectional study

Excess deaths associated with the Iranian COVID-19 epidemic: a province-level analysis

Seroprevalence of SARS-CoV-2 in Guilan province